ES2885573T3 - Nuevos compuestos de tetrazol y su uso en el tratamiento de la tuberculosis - Google Patents

Nuevos compuestos de tetrazol y su uso en el tratamiento de la tuberculosis Download PDF

Info

Publication number
ES2885573T3
ES2885573T3 ES18755815T ES18755815T ES2885573T3 ES 2885573 T3 ES2885573 T3 ES 2885573T3 ES 18755815 T ES18755815 T ES 18755815T ES 18755815 T ES18755815 T ES 18755815T ES 2885573 T3 ES2885573 T3 ES 2885573T3
Authority
ES
Spain
Prior art keywords
tetrazol
benzenesulfonamide
hydroxyethyl
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18755815T
Other languages
English (en)
Spanish (es)
Inventor
Carlos Alemparte-Gallardo
Lourdes Encinas
Provencio Jorge Esquivias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Application granted granted Critical
Publication of ES2885573T3 publication Critical patent/ES2885573T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES18755815T 2017-08-17 2018-08-16 Nuevos compuestos de tetrazol y su uso en el tratamiento de la tuberculosis Active ES2885573T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382574 2017-08-17
PCT/EP2018/072205 WO2019034729A1 (en) 2017-08-17 2018-08-16 NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS

Publications (1)

Publication Number Publication Date
ES2885573T3 true ES2885573T3 (es) 2021-12-14

Family

ID=59713960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18755815T Active ES2885573T3 (es) 2017-08-17 2018-08-16 Nuevos compuestos de tetrazol y su uso en el tratamiento de la tuberculosis

Country Status (19)

Country Link
US (1) US11072591B2 (https=)
EP (1) EP3668856B1 (https=)
JP (1) JP7410017B2 (https=)
KR (1) KR102661367B1 (https=)
CN (1) CN110997651B (https=)
AU (1) AU2018317812C1 (https=)
CA (1) CA3072854A1 (https=)
CY (1) CY1124577T1 (https=)
DK (1) DK3668856T3 (https=)
ES (1) ES2885573T3 (https=)
HR (1) HRP20211326T1 (https=)
HU (1) HUE055732T2 (https=)
LT (1) LT3668856T (https=)
PL (1) PL3668856T3 (https=)
PT (1) PT3668856T (https=)
RS (1) RS62267B1 (https=)
SI (1) SI3668856T1 (https=)
SM (1) SMT202100515T1 (https=)
WO (1) WO2019034729A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CN115403533B (zh) * 2021-05-28 2023-08-25 永康市第一人民医院 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用
CN116102483B (zh) * 2021-11-09 2025-01-17 中国医学科学院药物研究所 取代吡咯-2,5-二酮类化合物及其制备方法和用途
CN116726018A (zh) * 2023-08-02 2023-09-12 上海市肺科医院(上海市职业病防治院) 一种贝达喹啉、德拉马尼、氯法齐明和吡嗪酰胺的联用和应用
CN117379430A (zh) * 2023-10-11 2024-01-12 深圳市第三人民医院(深圳市肝病研究所) 一种地拉韦啶的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621427B2 (ja) 1997-07-22 2005-02-16 塩野義製薬株式会社 糸球体障害治療または予防剤
KR20120003499A (ko) * 2007-04-05 2012-01-10 지멘스 메디컬 솔루션즈 유에스에이, 인크. 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
WO2017066964A1 (en) 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
EP3668856B1 (en) 2021-06-23
WO2019034729A1 (en) 2019-02-21
BR112020003247A2 (pt) 2020-08-18
JP2020531425A (ja) 2020-11-05
CA3072854A1 (en) 2019-02-21
CN110997651A (zh) 2020-04-10
SMT202100515T1 (it) 2021-11-12
PL3668856T3 (pl) 2021-12-13
CY1124577T1 (el) 2022-07-22
RU2020110818A (ru) 2021-09-17
EP3668856A1 (en) 2020-06-24
US20200231555A1 (en) 2020-07-23
RS62267B1 (sr) 2021-09-30
US11072591B2 (en) 2021-07-27
KR20200041915A (ko) 2020-04-22
JP7410017B2 (ja) 2024-01-09
HRP20211326T1 (hr) 2021-11-26
CN110997651B (zh) 2023-01-03
PT3668856T (pt) 2021-09-15
AU2018317812B2 (en) 2021-04-15
DK3668856T3 (da) 2021-09-20
HUE055732T2 (hu) 2021-12-28
RU2020110818A3 (https=) 2021-10-11
AU2018317812A1 (en) 2020-02-20
AU2018317812C1 (en) 2021-08-26
KR102661367B1 (ko) 2024-04-29
SI3668856T1 (sl) 2021-11-30
LT3668856T (lt) 2021-09-27

Similar Documents

Publication Publication Date Title
ES2885573T3 (es) Nuevos compuestos de tetrazol y su uso en el tratamiento de la tuberculosis
EP3191478B1 (en) Compounds and compositions as raf kinase inhibitors
JP6764970B2 (ja) 三環式ベンゾキサボロール化合物及びその使用
US9694016B2 (en) Biaryl amide compounds as kinase inhibitors
JP6308504B2 (ja) タンパク質キナーゼ阻害薬
JP2021521131A (ja) ヒト免疫不全ウイルス複製の阻害剤としての4−オキソ−3,4−ジヒドロキナゾリン化合物
JP6646044B2 (ja) キナーゼ阻害剤としての化合物および組成物
US11427558B1 (en) Indazoles and azaindazoles as LRRK2 inhibitors
CN107531730B (zh) 4-取代苯并氧杂硼杂环戊烯化合物及其用途
WO2016133838A1 (en) Gdf-8 inhibitors
JP2018525372A (ja) 呼吸器合胞体ウイルス阻害剤
WO2021064677A1 (en) Inhibitors of human immunodeficiency virus replication
EP4041729A1 (en) Inhibitors of human immunodeficiency virus replication
KR20220122649A (ko) 신규한 약학 조성물(new pharmaceutical compounds)
RU2800930C2 (ru) Новые производные тетразола и их применение в лечении туберкулеза
BR112020003247B1 (pt) Compostos de tetrazol, uso dos ditos compostos para o tratamento de infecção micobacteriana ou de doença causada pela mesma, composição farmacêutica e combinação que compreende os compostos
ES2981834T3 (es) Quinolinas antibacterianas
TW202540100A (zh) 作為parp1抑制劑之化合物及包含其之醫藥組合物